XT
ABUS icon

XTX Topco’s Arbutus Biopharma ABUS Stock Holding History

XTX Topco’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
76,210
+36,189
+90% +$159K ﹤0.01% 2737
2026
Q1 		$180K Buy
+40,021
New +$175K ﹤0.01% 2882
2025
Q4 		– Sell
-11,364
Closed -$51.6K – 3258
2025
Q3 		$51.6K Sell
11,364
-12,550
-52% -$46.1K ﹤0.01% 2160
2025
Q2 		$73.9K Sell
23,914
-48,498
-67% -$161K ﹤0.01% 1938
2025
Q1 		$253K Buy
72,412
+19,831
+38% +$66.1K 0.01% 1536
2024
Q4 		$172K Buy
52,581
+22,568
+75% +$83K 0.01% 1614
2024
Q3 		$116K Buy
30,013
+12,975
+76% +$49.8K 0.01% 1581
2024
Q2 		$52.6K Buy
+17,038
New +$51.1K ﹤0.01% 1507
2022
Q4 		– Sell
-39,755
Closed -$76K – 1075
2022
Q3 		$76K Sell
39,755
-63,527
-62% -$150K 0.02% 985
2022
Q2 		$280K Buy
103,282
+92,494
+857% +$237K 0.11% 299
2022
Q1 		$32K Sell
10,788
-18,238
-63% -$55.8K 0.01% 615
2021
Q4 		$113K Buy
29,026
+17,422
+150% +$67.7K 0.06% 449
2021
Q3 		$50K Buy
+11,604
New +$38.7K 0.02% 604

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

XTX Topco's ABUS Position: Q2 2026 in Review

XTX Topco increased its Arbutus Biopharma (ABUS) stake by 90% in Q2 2026, buying an estimated $159K and bringing the position to 76,210 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #2737.

XTX Topco first reported a position in ABUS in Q3 2021 and has held it in 13 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • XTX Topco held 76,210 shares of Arbutus Biopharma worth $366K as of Q2 2026.
  • XTX Topco bought 36,189 Arbutus Biopharma shares in Q2 2026, an estimated $159K.
  • Arbutus Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #2737 holding.
  • XTX Topco first reported a position in Arbutus Biopharma in Q3 2021 and has held it in 13 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.